Takeaways

#
  • Verrone said healthcare was still in the bottom third of his rankings. Improving individual charts earned it more research time.
  • A turn in Gilead and a breakout in Novartis were among the early changes he wanted to investigate.
  • McLaughlin reported an existing June Pfizer risk reversal: short the $27.50 put, long the $32.50 call, for about a five-cent credit.

If Chris Verrone ran a healthcare portfolio and hadn’t looked closely at Gilead in two years, he knew what he’d ask his team to do that morning: reopen the file. Gilead’s chart had started to turn. In the same week, Novartis’s U.S.-traded shares had broken out of a range he estimated had held for seven or eight months.

Verrone, head of technical and macro research at Strategas, brought those examples to the January 4, 2024 Morning Show. Healthcare was still in the bottom third of his sector rankings. He hadn’t moved it to the top of his list. What had changed was that he could justify spending scarce research time on it.

Looking for the turn in individual stocks

The relative performance line for healthcare had edged above a downtrend that stretched back roughly a year. Verrone thought he could be a little more constructive in January than he’d been a month earlier, just as he’d been a little more constructive then than six months before. It mattered to him that the changes had begun before investors turned the calendar to 2024.

He usually spotted a shift in a group in its individual stocks first. Some healthcare companies already had strong charts. Others had fallen sharply in the second half of 2023 and bounced back to declining moving averages. What those stocks did on the next pullback would tell him more than the bounce itself. An orderly retreat, rather than another sharp selloff, would give him more confidence that participation was spreading.

A trade in one of the laggards

Later in the show, Sean McLaughlin described a different way to approach the same sector. Merck and Amgen had already run. Pfizer hadn’t, but its shares had briefly broken below a support area visible on a chart going back more than a decade. McLaughlin thought the breakdown might fail. He liked having a nearby level that could tell him he was wrong.

He said he sold the June $27.50 Pfizer puts and used the proceeds to buy the June $32.50 calls, taking in a net credit of about five cents. If Pfizer finished between the two strikes at expiration, both options could expire worthless and he’d keep that credit. If Pfizer fell below $27.50, he could be assigned on the put and have to buy the shares at the strike even if they were worth less.

Questions and answers

#

Questions answered in the original 2024-01-04 episode.

Which two drugmakers did Verrone use to illustrate improving charts?

He pointed to a turn in Gilead and a breakout in Novartis’s U.S.-traded shares after about seven or eight months in a range.

Link to this answer

Was the five-cent Pfizer credit McLaughlin’s maximum loss?

No. It was the net premium he said he collected. A decline below the $27.50 put strike exposed the short put to losses; he discussed using a nearby chart level to manage that risk.

Link to this answer

Adapted by Stock Market TV Editorial from the original video. Source date: . Article published: .